Medicine guide

ELAPRASE

As listed in the register: ELAPRASE 2 mg/ml, solution à diluer pour perfusion

2 mg · solution à diluer pour perfusion

  • Prescription only
Active substance
Idursulfase
Made by
TAKEDA PHARMACEUTICALS INTERNATIONAL (IRLANDE)

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

United StatesNo exact match for this strength and form

European UnionNo exact match for this strength and form

CanadaNo exact match for this strength and form

NetherlandsNo exact match for this strength and form

Details

Made byTAKEDA PHARMACEUTICALS INTERNATIONAL (IRLANDE)
Active substanceIdursulfase
Strength2 mg
Formsolution à diluer pour perfusion
Routeintraveineuse
Dispensing (as stated by the register)prescription hospitalière · liste I · la première administration doit être effectuée en milieu hospitalier
MarketedYes, according to the register
Reinforced monitoringYes — under reinforced monitoring, according to the register
Authorisation procedureProcédure centralisée
EU numberEU/1/06/365
Name in the registerELAPRASE 2 mg/ml, solution à diluer pour perfusion
Packs1 flacon(s) en verre de 3 ml · 1 flacon(s) en verre de 3 ml ( abrogée le 02/05/2022)
CIS63288174
CIP133400930236536
CIP133400957056339

Source: Base de données publique des médicaments · 2026-09-30 · not reviewed by a clinician

Source : Base de données publique des médicaments (ANSM / Ministère de la Santé), sous Licence Ouverte. Reuse terms: Licence Ouverte / Open Licence (Etalab).